CoChat

Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial

Open access
Rebelatto, Carmen Lúcia Kuniyoshi, Senegaglia, Alexandra Cristina, Franck, Claudio Luciano, Daga, Debora Regina, Shigunov, Patrícia, Stimamiglio, Marco Augusto, Marsaro, Daniela Boscaro, Schaidt, Bruna, Micosky, Andressa, de Azambuja, Ana Paula, Leitão, Cleverson Alex, Petterle, Ricardo Rasmussen, Jamur, Valderez Ravaglio, Vaz, Isadora May, Mallmann, Antônio Paulo, Carraro Junior, Hipólito, Ditzel, Eduardo, Brofman, Paulo Roberto Slud, Correa, Alejandro · 2022 · Stem Cell Research & Therapy
Cited by 56

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Background: COVID-19 is a multisystem disease that presents acute and persistent symptoms, the postacute sequelae (PASC). Long-term symptoms may be due to consequences from organ or tissue injury caused by SARS-CoV-2, associated clotting or inflammatory processes during acute COVID-19. Various strategies are being chosen by clinicians to prevent severe cases of COVID-19; however, a single treatment would not be efficient in treating such a complex disease. Mesenchymal stromal cells (MSCs) are known for their immunomodulatory properties and regeneration ability; therefore, they are a promising tool for treating disorders involving immune dysregulation and extensive tissue damage, as is the case with COVID-19. This study aimed to assess the safety and explore the long-term efficacy of three intravenous doses of UC-MSCs (umbilical cord MSCs) as an adjunctive therapy in the recovery and postacute sequelae reduction caused by COVID-19. To our knowledge, this is one of the few reports that presents the longest follow-up after MSC treatment in COVID-19 patients. Methods: This was a phase I/II, prospective, single-center, randomized, double-blind, placebo-controlled clinical trial. Seventeen patients diagnosed with COVID-19 who require intensive care surveillance and invasive mechanical ventilation—critically ill patients—were included. The patient infusion was three doses of 5 × 10 5 cells/kg UC-MSCs, with a dosing interval of 48 h ( n = 11) or placebo ( n = 6). The evaluations consisted of a clinical assessment, viral load, laboratory testing, including blood count, serologic, biochemical, cell subpopulation, cytokines and CT scan. Results: The results revealed that in the UC-MSC group, there was a reduction in the levels of ferritin, IL-6 and MCP1-CCL2 on the fourteen day. In the second month, a decrease in the levels of reactive C-protein, D-dimer and neutrophils and an increase in the numbers of TCD3, TCD4 and NK lymphocytes were observed. A decrease in extension of lung damage was observed at the fourth month. The improvement in all these parameters was maintained until the end of patient follow-up. Conclusions: UC-MSCs infusion is safe and can play an important role as an adjunctive therapy, both in the early stages, preventing severe complications and in the chronic phase with postacute sequelae reduction in critically ill COVID-19 patients. Trial registration Brazilian Registry of Clinical Trials (ReBEC), UTN code-U1111-1254-9819. Registered 31 October 2020—Retrospectively registered, https://ensaiosclinicos.gov.br/rg/RBR-3fz9yr

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13287-022-02796-1

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 21 references

Cited by

See all 56

Metadata

Authors
Rebelatto, C. L. K., Senegaglia, A. C., Franck, C. L., Daga, D. R., Shigunov, P., Stimamiglio, M. A., Marsaro, D. B., Schaidt, B., Micosky, A., de Azambuja, A. P., Leitão, C. A., Petterle, R. R., Jamur, V. R., Vaz, I. M., Mallmann, A. P., Carraro Junior, H., Ditzel, E., Brofman, P. R. S., & Correa, A.
Venue
Stem Cell Research & Therapy
Published
2022-03-21
Volume
13
Issue
1
Pages
122-122
ISSN
1757-6512 (ISSN-L)
OpenAlex
W4220803992
Cited by
56
References
21
FWCI
6.36
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial. https://app.cochat.ai/papers/10.1186/s13287-022-02796-1
The paper
Rebelatto, C. L. K., Senegaglia, A. C., Franck, C. L., Daga, D. R., Shigunov, P., Stimamiglio, M. A., Marsaro, D. B., Schaidt, B., Micosky, A., de Azambuja, A. P., Leitão, C. A., Petterle, R. R., Jamur, V. R., Vaz, I. M., Mallmann, A. P., Carraro Junior, H., Ditzel, E., Brofman, P. R. S., & Correa, A. (2022). Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-022-02796-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.